Ad is loading...
ESCGX
Price
$10.31
Change
-$0.07 (-0.67%)
Updated
Nov 15 closing price
RNWFX
Price
$80.56
Change
-$0.79 (-0.97%)
Updated
Nov 15 closing price
Ad is loading...

ESCGX vs RNWFX

Header iconESCGX vs RNWFX Comparison
Open Charts ESCGX vs RNWFXBanner chart's image
Ashmore Emerging Markets Equity ESG C
Price$10.31
Change-$0.07 (-0.67%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$80.56
Change-$0.79 (-0.97%)
VolumeN/A
CapitalizationN/A
ESCGX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
ESCGX vs. RNWFX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESCGX is a StrongSell and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 60.9B vs. ESCGX (12.5M). RNWFX pays higher dividends than ESCGX: RNWFX (1.51) vs ESCGX (0.03). ESCGX was incepted earlier than RNWFX: ESCGX (5 years) vs RNWFX (23 years). ESCGX is a more actively managed with annual turnover of: 51.00 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than ESCGX: RNWFX (250) vs ESCGX (1000). ESCGX annual gain was more profitable for investors over the last year : 12.92 vs. RNWFX (11.54).
ESCGXRNWFXESCGX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years23 years-
Gain YTD8.0717.099114%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets12.5M60.9B0%
Annual Yield % from dividends0.031.512%
Returns for 1 year12.9211.54112%
Returns for 3 years-30.54-14.55210%
Returns for 5 yearsN/A17.17-
Returns for 10 yearsN/A41.00-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRNA35.660.29
+0.82%
Verona Pharma plc
BURL268.94-0.65
-0.24%
Burlington Stores
RCMT22.25-0.38
-1.68%
RCM Technologies
SNTI2.15-0.18
-7.73%
Senti Biosciences Inc.
CATX7.88-1.04
-11.66%
Perspective Therapeutics